EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions

Tinglin Yang iD, Wenhui Li, Tao Huang iD, Jun Zhou

International Journal of Molecular Sciences · 25.07.2023 · 24 (15) · 11903

DOI: 10.3390/ijms241511903 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.07.2023. Verfasst von Tinglin Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Immunoconjugates. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Program of Natural Science Foundation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To achieve the scheme of “magic bullets” in antitumor therapy, antibody-drug conjugates (ADCs) were developed. ADCs consist of antibodies targeting tumor-specific antigens, chemical linkers, and cytotoxic payloads that powerfully kill cancer cells. With the approval of ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan (T-DXd), the therapeutic potentials of ADCs in breast cancer have come into the spotlight. Nearly 30 ADCs for breast cancer are under exploration to move targeted therapy forward. In this review, we summarize the presenting and emerging agents and targets of ADCs. The ADC structure and development history are also concluded. Moreover, the challenges faced and prospected future directions in this field are reviewed, which give insights into novel treatments with ADCs for breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic AgentsImmunoconjugatesHumansFemaleTrastuzumabAdo-Trastuzumab Emtansine

Stichwörter der Autor:innen

antibody-drug conjugatesbreast cancertargeted therapy

Substanzen

TrastuzumabAntineoplastic AgentsAdo-Trastuzumab EmtansineImmunoconjugates

Autor:innen und Institutionen

  • Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

ORCID-Profile: Tinglin Yang, Tao Huang

Förderung

  • Key Program of Natural Science Foundation of Hubei Province

Zitieren

APA

Yang, T., Li, W., Huang, T., & Zhou, J. (2023). Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions. International Journal of Molecular Sciences, 24(15), 11903. https://doi.org/10.3390/ijms241511903

Vancouver

Yang T, Li W, Huang T, Zhou J. Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions. International Journal of Molecular Sciences. 2023;24(15):11903. doi:10.3390/ijms241511903

BibTeX
@article{Yang2023,
  author = {Yang, Tinglin and Li, Wenhui and Huang, Tao and Zhou, Jun},
  title = {Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {15},
  pages = {11903},
  doi = {10.3390/ijms241511903}
}
Kostenlos starten →